List of Excipients in Branded Drug NORETHINDRONE

« Back to Dashboard

Generic Drugs Containing NORETHINDRONE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	norethindrone	0378-7272	ANHYDROUS LACTOSE
Mylan Pharmaceuticals Inc	norethindrone	0378-7272	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	norethindrone	0378-7272	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in NORETHINDRONE?

# Of NDCs	Excipient
1	ACID YELLOW 3
9	ANHYDROUS LACTOSE
5	CELLULOSE, MICROCRYSTALLINE

Norethindrone Excipient Strategy and Commercial Opportunities

Last updated: October 23, 2026

Norethindrone is a mature, low-cost progestin with limited value in core-molecule exclusivity and greater opportunity in differentiated delivery, tolerability, packaging, and lifecycle management. The strongest commercial targets are low-dose oral products, norethindrone acetate tablets, reproductive-health combination products, and regulated consumer-health extensions. Excipient selection should prioritize dose uniformity, rapid and reproducible dissolution, moisture control, patient acceptability, and manufacturing cost.

What products contain norethindrone and norethindrone acetate?

Norethindrone and norethindrone acetate are related but distinct active pharmaceutical ingredients. Norethindrone acetate is the acetate ester of norethindrone and is used extensively in higher-dose gynecologic products.

Product category	Typical strength	Principal use	Commercial status
Norethindrone tablets	0.35 mg	Progestin-only contraception	Generic, multi-manufacturer
Norethindrone acetate tablets	5 mg	Abnormal uterine bleeding, endometriosis, amenorrhea	Generic, multi-manufacturer
Ethinyl estradiol/norethindrone tablets	Various	Combined oral contraception	Generic, multi-manufacturer
Ethinyl estradiol/norethindrone acetate products	Various	Contraception and menopausal therapy	Generic or branded, depending on product
Norethindrone extended-cycle products	Various	Extended-cycle contraception	Product-specific

FDA-approved labels identify norethindrone 0.35 mg products under several generic and branded names, including Camila, Errin, Heather, Jencycla, Nora-BE, and Norlyroc. Norethindrone acetate 5 mg products include generic equivalents to Aygestin and are used for gynecologic indications.[1-3]

The two principal formulation problems differ by strength:

• The 0.35 mg tablet requires highly controlled content uniformity because the active load is very low.
• The 5 mg tablet allows more conventional direct-compression or wet-granulation designs but must maintain dissolution and physical stability over long shelf lives.

What excipients are used in norethindrone tablets?

Commercial norethindrone tablets generally use conventional immediate-release excipients. Common classes include lactose or another diluent, starch or pregelatinized starch, povidone or another binder, colloidal silicon dioxide as a glidant, and magnesium stearate as a lubricant.[1,2]

Typical excipient functions are:

Excipient class	Examples	Primary function	Key risk
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Provides tablet mass and improves manufacturability	Density variation, lactose intolerance positioning
Disintegrant	Corn starch, sodium starch glycolate, crospovidone, croscarmellose sodium	Promotes tablet breakup	Excessive swelling or slower dissolution
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength	Overbinding and delayed release
Glidant	Colloidal silicon dioxide	Improves powder flow	Segregation if overused
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces tooling friction	Hydrophobic film and dissolution delay
Colorant	Iron oxides, FD&C dyes	Product identification	Regulatory and patient-acceptability issues
Film former	Hypromellose, polyethylene glycol, titanium dioxide where permitted	Protection, appearance, swallowability	Added process complexity

The excipient package should not be selected solely from a low-cost generic template. Norethindrone's low dose makes blend uniformity, segregation, and sampling strategy more important than the nominal quantity of excipient.

How should excipients be selected for 0.35 mg norethindrone tablets?

A robust 0.35 mg product should use a formulation and process that reduce active segregation. The main options are:

1. Ordered mixing with a carrier excipient.
2. Wet granulation to distribute the drug through a larger granule population.
3. Dry granulation when moisture sensitivity, process cost, or scale favors roller compaction.
4. Spray-dried or co-processed excipient systems where flow and content uniformity remain difficult.

Microcrystalline cellulose can improve compactability, while lactose can support acceptable flow and rapid disintegration. However, lactose-based blends may require tighter control of particle-size distribution and density matching between drug and diluent.

Crospovidone or croscarmellose sodium can support rapid disintegration at low concentrations. Excessive levels can increase tablet porosity, friability, or manufacturing cost without improving clinical performance.

Magnesium stearate should be optimized by mixing time and specific surface-area control. Overlubrication can slow dissolution, particularly in tablets with high lubricant exposure and low drug loading.

What excipient strategy is strongest for norethindrone acetate 5 mg?

Norethindrone acetate 5 mg offers more formulation latitude. A conventional immediate-release tablet can use a directly compressible diluent system, but a differentiated product can compete on swallowability, dissolution robustness, or excipient exclusion.

A practical development platform would include:

• Microcrystalline cellulose or a co-processed diluent for compactability.
• Crospovidone or croscarmellose sodium for rapid breakup.
• Povidone or hydroxypropyl cellulose only if granule strength requires it.
• Colloidal silicon dioxide for flow.
• Magnesium stearate or sodium stearyl fumarate at a controlled level.
• Film coating for moisture protection, identification, and improved swallowing.

Norethindrone acetate products may be attractive for an excipient-reduced or “clean-label” positioning strategy. The commercial value of that strategy depends on the target market. Prescribers generally prioritize availability, dose reliability, insurance coverage, and tolerability. Patients and cash-pay channels may respond more strongly to lactose-free, dye-free, gluten-free, or low-allergen claims, provided those claims are supported by the complete formulation and labeling.

What formulation patents protect norethindrone products?

The core norethindrone and norethindrone acetate molecules are legacy compounds. Core composition-of-matter exclusivity is not a meaningful barrier to generic entry. Commercial protection, where available, is more likely to arise from:

• Modified-release dosage forms.
• Extended-cycle contraceptive regimens.
• Specific combination products.
• Novel dissolution or bioavailability systems.
• Packaging and adherence technologies.
• Manufacturing processes.
• Method-of-use claims tied to a particular regimen or patient population.

A formulation patent can protect a specific excipient ratio, particle-size distribution, coating system, release profile, or manufacturing sequence. Its value depends on claim breadth, enablement, freedom-to-operate exposure, and whether the formulation is listed in the FDA Orange Book.

For a new norethindrone product, patent drafting should focus on measurable attributes rather than generic excipient lists. Stronger claim concepts may include:

• A defined dissolution profile across multiple pH conditions.
• A low-dose blend with a specified content-uniformity range.
• A particle-size or solid-state limitation linked to performance.
• A reduced-excipient formulation with a defined disintegration time.
• A moisture-stable formulation using a specified packaging configuration.
• A controlled-release dosage form with clinically relevant pharmacokinetic performance.

Broad claims covering “norethindrone plus a diluent and disintegrant” are vulnerable because conventional excipient combinations are likely to be anticipated or obvious.

What is the Orange Book status of norethindrone products?

FDA Orange Book protection is product-specific. Norethindrone and norethindrone acetate products have extensive generic competition, and legacy immediate-release products generally do not depend on active, commercially significant compound patents.[4]

Orange Book analysis should distinguish among:

• The reference listed drug.
• Approved generic products.
• Listed patents, if any.
• Pediatric exclusivity.
• New chemical entity exclusivity.
• Three-year exclusivity for a qualifying supplemental approval.
• Any listed formulation or method-of-use patents.

For a prospective applicant, the relevant regulatory pathway will usually be an abbreviated new drug application, provided the reference product and dosage form support an ANDA pathway. A genuinely novel delivery system may instead require a 505(b)(2) application, depending on the degree of formulation and clinical differentiation.[5]

When does norethindrone lose exclusivity?

Norethindrone's original chemical exclusivity expired decades ago. Current commercial barriers are therefore regulatory and operational rather than molecule-based.

Exclusivity type	Relevance to legacy norethindrone products
Original composition-of-matter patent	Expired
New chemical entity exclusivity	Expired
Standard generic competition	Established
Product-specific formulation patent	Possible only for a newer formulation
Pediatric exclusivity	Product-specific and generally not central to legacy products
505(b)(2) exclusivity	Possible for a qualifying new product, but not automatic
Orphan-drug exclusivity	Generally not relevant to standard norethindrone indications

Exact patent expiration analysis must be performed against the current Orange Book, Patent and Exclusivity Register, and relevant patent-family records for the specific product.[4]

What Paragraph IV challenges affect norethindrone?

Paragraph IV litigation is not ordinarily the central risk for conventional norethindrone 0.35 mg or norethindrone acetate 5 mg tablets because multiple generic products are already approved and marketed. Paragraph IV risk becomes more relevant when a company develops:

• A new extended-release norethindrone product.
• A proprietary combination product.
• A new indication supported by clinical studies.
• A formulation with Orange Book-listed patents.
• A branded product with an active patent estate.

For a legacy immediate-release product, the more material risks are abbreviated new drug application competition, price erosion, manufacturing discontinuation, and wholesaler concentration.

How strong is the patent estate for norethindrone?

The patent estate for the active ingredient is weak as a barrier to conventional generic competition. A new product can still create a stronger estate around formulation and use, but the estate will not prevent substitution unless it covers a commercially important attribute and survives validity and infringement scrutiny.

Patent category	Relative strength for a new norethindrone product	Commercial assessment
Core molecule	Low	Historic protection is expired
Standard immediate-release tablet	Low	Conventional excipient systems are crowded
Low-dose content-uniformity process	Moderate	Useful if claims are specific and performance-linked
Modified release	Moderate to high	Can support differentiation if clinically relevant
Combination product	Moderate	Depends on ingredients, regimen, and prior art
Packaging and adherence system	Moderate	More useful for lifecycle protection than generic blocking
Method of treatment	Variable	Must align with approved indication and enforceable claim scope
Manufacturing process	Moderate	Valuable if difficult to design around and linked to product quality

The most defensible strategy is a layered estate: formulation claims, process claims, product-by-process limitations where legally viable, packaging claims, and method claims. The claims should be supported by comparative data against marketed generic products.

What manufacturing and intellectual-property barriers matter?

The principal manufacturing barriers are low-dose uniformity, scale-up reproducibility, blend segregation, dissolution control, and tablet friability. These are manageable but can create meaningful operational differentiation.

A manufacturer should generate data on:

• Blend assay and content-uniformity performance.
• Segregation after transfer and hopper hold time.
• Lubrication sensitivity.
• Tablet tensile strength and friability.
• Disintegration across compression-force ranges.
• Dissolution in relevant media.
• Stability under accelerated and long-term conditions.
• Packaging performance under humidity exposure.
• Extractables and leachables for bottles, liners, and blister systems.

Excipient suppliers can create commercial value by offering co-processed systems, low-moisture grades, high-functionality binders, and excipient packages designed for continuous manufacturing. The strongest opportunity is not a new excipient molecule. It is a validated formulation platform that lowers development time and improves batch release reliability.

What commercial opportunities exist for norethindrone excipients?

Generic manufacturers

Generic manufacturers can compete through:

• Lower tablet weight.
• Lactose-free or dye-free formulations.
• Faster disintegration.
• Improved tablet hardness without dissolution loss.
• Reduced batch failure risk.
• Regional manufacturing and supply security.
• Unit-dose blister packaging.
• Dual-source excipient procurement.

The economic model is volume-driven. A low-cost formulation must withstand aggressive price competition, so process yield and supply continuity matter more than small differences in ingredient cost.

Specialty pharmaceutical companies

Specialty companies can pursue:

• Extended-cycle contraception.
• Long-acting or depot delivery systems.
• Transdermal or buccal systems.
• Lower-dose regimens.
• Combination products with improved tolerability.
• Products for abnormal uterine bleeding or endometriosis with differentiated dosing.
• 505(b)(2) products supported by new pharmacokinetic or clinical data.

These programs carry higher development and regulatory costs. Their value depends on demonstrating a clinical or adherence advantage rather than merely changing tablet appearance.

Excipient manufacturers

Excipient suppliers can target:

1. Co-processed direct-compression systems for low-dose APIs.
2. Low-peroxide excipients for oxidation-sensitive formulations.
3. Moisture-protective excipient blends.
4. Fast-disintegrating systems for small tablets.
5. Excipient packages compatible with continuous manufacturing.
6. Dye-free and lactose-free platforms.
7. Film-coating systems that improve swallowability without delaying dissolution.

Supplier differentiation should be supported by application data using norethindrone or a comparable low-dose, poorly distributed model API.

Contract development and manufacturing organizations

CDMOs can package norethindrone development services around:

• Formulation screening.
• Blend-uniformity optimization.
• Comparative dissolution.
• Scale-up from pilot to commercial batches.
• ANDA support.
• 505(b)(2) development.
• Stability and packaging programs.
• Technology transfer to regional manufacturing sites.

A CDMO with validated low-dose blending and robust content-uniformity controls can command a stronger position than one offering only standard tablet compression.

How does norethindrone compare with other progestins?

Norethindrone competes with levonorgestrel, norgestrel, drospirenone, medroxyprogesterone acetate, and newer progestins depending on indication and dosage form.

Attribute	Norethindrone	Levonorgestrel	Drospirenone	Medroxyprogesterone acetate
Generic availability	Extensive	Extensive	Increasing	Extensive
Progestin-only oral use	Established	Established	Established in newer products	Limited for this role
Low-dose tablet challenge	High	High	High	Moderate
Modified-release opportunity	Possible	Possible	Possible	Product-specific
Legacy patent barrier	Low	Low	Product-specific	Low
Excipient differentiation	Moderate	Moderate	Moderate	Moderate
Main commercial advantage	Established use and supply base	Broad contraceptive familiarity	Newer product positioning	Diverse dosage forms

Norethindrone's commercial advantage is its established regulatory history and broad manufacturing base. Its disadvantage is intense price competition and limited exclusivity for conventional products.

What generic launch scenarios exist?

Immediate-release generic launch

This is the lowest-risk scenario operationally but usually has the greatest price pressure. Success depends on cost of goods, supply reliability, customer contracts, and rapid regulatory execution.

Differentiated excipient launch

A lactose-free, dye-free, lower-tablet-weight, or improved-swallowability product can create modest commercial differentiation. These attributes are more valuable in cash-pay, specialty-pharmacy, and patient-direct channels than in highly commoditized payer channels.

505(b)(2) modified-release launch

A modified-release product can command greater pricing power, but it requires stronger clinical, pharmacokinetic, and patent support. The development program must establish a meaningful benefit over immediate-release tablets.

Combination-product launch

Combination products can expand market access and support product-specific protection. They also introduce additional analytical, clinical, labeling, and supply-chain requirements.

What revenue exposure exists?

Revenue exposure is concentrated in high-volume generic oral contraceptive and gynecologic markets. Individual-product revenue is difficult to estimate from public information because manufacturers often report norethindrone within broader women's-health or generic portfolios.

The main revenue drivers are:

• Number of approved manufacturers.
• Payer substitution rules.
• Wholesale acquisition price.
• Pharmacy reimbursement.
• Back-order frequency.
• Contract manufacturing cost.
• Active ingredient and excipient supply.
• Product discontinuations.
• Brand or authorized-generic status.

The principal downside is rapid price erosion after additional generic entry. The principal upside is supply disruption in a concentrated market, where a reliable manufacturer can gain share without introducing a new clinical product.

Key Takeaways

• Norethindrone and norethindrone acetate are mature APIs with no meaningful remaining core-molecule exclusivity.
• The 0.35 mg tablet is primarily a content-uniformity and segregation challenge.
• The 5 mg norethindrone acetate tablet permits broader excipient and manufacturing choices.
• Conventional excipient patents are unlikely to create strong market barriers unless tied to measurable performance.
• The strongest formulation opportunities are modified release, low-dose uniformity, improved swallowability, moisture protection, and excipient-reduced designs.
• ANDA competition is the normal pathway for conventional products; 505(b)(2) may apply to genuinely differentiated delivery systems.
• Excipient suppliers and CDMOs can create value through validated low-dose manufacturing platforms rather than commodity ingredient supply alone.
• Commercial returns are likely to come from cost control, supply reliability, packaging, and lifecycle differentiation rather than from the legacy active ingredient.

FAQs

Can lactose-free norethindrone tablets create a meaningful commercial advantage?

Yes, but the advantage is segment-specific. Lactose-free products can support patient and pharmacy differentiation, although payer formularies may still treat them as interchangeable generic products.

Is a fast-disintegrating norethindrone tablet likely to receive new exclusivity?

Not automatically. Regulatory exclusivity requires a qualifying legal pathway, while patent protection depends on novel, non-obvious claims supported by comparative performance data.

Are excipient suppliers exposed to norethindrone patent litigation?

Exposure is generally limited for conventional excipients. Risk increases when a supplier knowingly supports a formulation covered by enforceable composition, process, or method claims.

Can norethindrone be developed as a long-acting injectable?

It is technically possible, but the program would require substantial formulation, pharmacokinetic, safety, and clinical work. The commercial case would depend on whether the delivery system improves adherence or addresses a gap left by existing long-acting contraceptives.

What is the most attractive near-term norethindrone opportunity?

The strongest near-term opportunity is a reliable, low-dose oral product with validated content uniformity, competitive cost, differentiated packaging, and a targeted excipient profile such as lactose-free or dye-free. A modified-release product offers greater upside but materially higher development risk.

References

1. DailyMed. (n.d.). Norethindrone tablet, 0.35 mg: Prescribing information. U.S. National Library of Medicine.
2. DailyMed. (n.d.). Norethindrone acetate tablet, 5 mg: Prescribing information. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book.
5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA Center for Drug Evaluation and Research.